Foscenvivint

Overview

PRI-724 is a selective inhibitor of the CBP/β-catenin interaction.

Application

Products | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Hypertension | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Signaling Pathways > Wnt

Product Information

• Catalog No.: HY-112045
• CAS No.: 1422253-38-0
• Molecular Formula: C33H35N6O7P
• Molecular Weight: 658.64
• Purity: 99.56%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 2.5 mg/mL (3.80 mM); Clear solution
• Availability: In-stock

Source

Original product source